Abstract
Introduction
Gastric cancer (GC) is a leading cause of cancer death worldwide [1] , with Helicobacter pylori (H. pylori) considered to be a main risk factor [2] . In Correa's hypothesis, chronic infection with H. pylori has been postulated to develop over decades into chronic gastritis, gastric atrophy, usually intestinal metaplasia (IM), dysplasia, and GC [2] .
To date, some meta-analyses have shown that H. pylori eradication reduced the risk of GC not only in patients with chronic gastritis but also in patients who underwent endoscopic resection for early GC [3] [4] [5] [6] [7] [8] . On the other hand, although several studies have been done regarding the effect of H. pylori eradication for the prevention of metachronous GC, the results remain controversial: some studies have shown that H.
pylori treatment led to a lower incidence of metachronous GC [9-11] and others have not [12] [13] [14] . Long-term studies from Japan showed that even after H. pylori eradication, the risk of the development of GC remains, and the risk increases in the preneoplastic conditions of the background mucosa, i.e., gastric atrophic mucosa (AM) and IM [15, 16] . These results indicate that H. pylori eradication treatment may reduce the risk of GC, although the risk is not abolished.
Aspirin also has protective effects against certain cancers. Recent reports including meta-analyses have shown that long-term aspirin use (at least more than 3 years) was associated with a reduced GC risk [17] [18] [19] [20] . However, the majority of these studies included both H. pylori-infected and H. pylori-negative subjects. Cheung et al. showed that the risk significantly decreased with increasing frequency, duration, and dose of aspirin after H. pylori eradication [21] .
GC develops through the accumulation of genetic and epigenetic alterations. Many studies have reported that several epigenetic alterations, including promoter hypermethylation of multiple tumor-related genes, are associated with GC and precancerous conditions of the stomach from the viewpoint of H. pylori infection [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . These reports demonstrate that H. pylori eradication led to a decrease in methylation levels at some genes [22] [23] [24] [25] [26] [27] , thus suggesting that the reduction of gene methylation reverse H. pylori-induced gastric carcinogenesis. However, there are no studies except ours [33, 34] and a study by Huang et al. [32] in which molecular events were analyzed in AM and IM separately using laser capture microdissection (LCM); thus, the actual effects of eradication therapy on molecular alteration in the precancerous conditions are not well known.
Currently, microRNAs (miRNAs) are considered to be actively involved in the development, differentiation, and pathogenesis of various malignancies. By comparing the miRNA expression profiles in tumor tissues versus adjacent non-tumor tissues, distinct patterns of up-or down-regulation of miRNAs could be found in different types of cancers [35] . Therefore, these cancer-specific miRNA expressions could be used as molecular biomarkers for GC. Indeed, several studies showed that the dysgeneration of some miRNAs by methylation highlights the useful biomarkers of GC development [29] [30] [31] [35] [36] [37] [38] [39] [40] [41] . Japanese investigators have recently reported that miR-124a-3 and miR-34b/c methylation are informative markers for predicting the risk of metachronous GC in patients after endoscopic resection of early GC [29, 36, 37] . However, we reported that the incidences of methylation of miR-124a-3 and miR-34c were mostly observed in IM, with very few in AM [33, 34] . Thus, our previous results indicate that the methylation of these miRNA genes might be a specific marker expressed in IM and might not necessarily be a risk marker for GC.
Our aim in this study was: 1) to investigate the methylation changes of several miRNAs related to gastric carcinogenesis in patients before and after H. pylori eradication in patients not taking low-dose aspirin (LDA) or nonsteroidal anti-inflammatory drugs (NSAIDs) (Cohort 1); and 2) to examine the effects of LDA/NSAIDs on the methylation status of those miRNAs before and after H. pylori eradication in patients who had regularly taken LDA/NSAIDs on a long-term basis (≥ 3 yr) (Cohort 2) in the precancerous conditions, i.e., AM and IM.
Results

Patients' characteristics
The characteristics of the patients are shown in Table 1 . In both Cohorts 1 and 2, there were no significant differences in median age or sex between the atrophic gastritis (AG) and GC groups in H. pylori-infected and -eradicated patients. However, the number of IM samples was significantly higher in the Hp-/GC and Hp-/LDA/GC groups than in the Hp+/AG and Hp+/LDA/AG groups (p=0.01 and p=002, respectively). In H. pylori-infected patients, the incidence of miR-124a-3 methylation in the Hp+/AG group was 31.7% and that of the methylation of other miRNA genes was very low (Table 3) . However, the miR-34c and miR-129-2 methylation rates were significantly higher in the Hp+/GC group than in the Hp+/AG group (p=0.0002 and p=0.004, respectively) ( Table 3 ). Multivariate analysis showed that miR-129-2 methylation in AM was significantly associated with GC (OR: 5.211, 95% CI:
1.460-18.597, p=0.011). When comparing the methylation rates of these miRNAs in AM among the three different parts of the stomach, the miR-34-c methylation rate in the Hp+/GC group was significantly higher in the antrum (p=0.03) and corpus (p=0.01) than in the Hp+/AG group ( Figure 1A) . Also, miR-129-2 methylation in AM in the corpus was more frequently identified in the Hp+/GC group than in the Hp+/AG group (p=0.01) ( Figure 1A ). Table 3 . Comparison of molecular alterations in AM between patients with and without GC in H. pylori-infected and -eradicated patients
Hp, H. pylori; AG, atrophic gastritis; GC, gastric cancer; AM, atrophic mucosa; OR, odds ratio; CI, confidence interval.
In H. pylori-eradicated cases, there were few methylations in all miRNAs in both the Hp-/AG and the Hp-/GC groups, and there was no significant difference in the incidence of miRNA methylation between the two groups (Table 3) . However, the miR-129-2 methylation rate in the angulus was significantly higher in the Hp-/GC group than in the Hp-/AG group (p=0.01) ( Figure 1B ). Figure 1 . Incidences of miRNA methylation in AM in three different parts of the stomach in patients not taking LDA/NSAIDs. (A) In H. pylori-infected patients, the miR-34-c methylation rate in the Hp+/GC group was significantly higher in the antrum (p=0.03) and corpus (p=0.01) than that in the Hp+/AG group. Also, miR-129-2 methylation in AM in the corpus was more frequently identified in the Hp+/GC group than in the Hp+/AG group (p=0.01). (B) In H. pylori-eradicated patients, the miR-129-2 methylation rate in the Hp-/GC group was significantly higher in the angulus than that in the Hp-/AG group (p=0.01). LDA, low-dose aspirin; NSAID, nonsteroidal anti-inflammatory drug.
Molecular events in IM
The incidence of all miRNA genes in IM was demonstrably higher compared to that in AM regardless of the presence or absence of H. pylori infection in both the AG and GC groups (Tables 4 and 5 ), a finding that was consistent with our previous report [28] .
Therefore, there were no significant differences in the methylation rates for each miRNA gene among the four groups, i.e., the Hp+/AG, Hp-/AG, Hp+/GC, and Hp-/GC groups. Furthermore, no significant differences in the incidence of miRNA gene methylation were seen between the AG and GC groups in each part of the stomach in both H. pylori-infected and -eradicated patients, unlike in AM (Supplementary Table   S1 ). (Table 6 ), a result that was different from the findings in Cohort 1.
However, only miR-129-2 methylation was more frequently observed in the Hp-/LDA/GC group than in the Hp-/LDA/AG group (p=0.02) among the H.
pylori-eradicated patients, although there were no significant differences in the incidences of the methylation of other miRNAs between the AG and GC groups regardless of the presence or absence of H. pylori infection (Table 7) . When looking at the methylation rate in each portion of the stomach, the miR-129-2 methylation rate was found to be significantly higher in the Hp-/LDA/GC group than in the Hp-/LDA/AG (p=0.04) group only in the antrum ( Figure 2B ). In H. pylori-eradicated patients, the miR-129-2 methylation rate in the Hp-/GC group was significantly higher in the antrum than that in the Hp-/AG group (p=0.04). LDA, low-dose aspirin; NSAID, nonsteroidal anti-inflammatory drug. 
Molecular alterations in IM
The incidences of methylation of all miRNA genes in IM were higher compared to those in AM, and they were not significantly different between the Hp+/LDA/AG and Hp-/LDA/AG groups nor between the Hp+/LDA/GC and Hp-/LDA/GC groups, which was similar to the results in AM (Table 8) . Similarly, there were no significant differences in the incidences of methylation of all miRNAs between the AG and GC groups regardless of the presence or absence of H. pylori infection (Table 9 ). In addition, no positive associations in the incidence of miRNA gene methylation were seen between the AG and GC groups in each part of the stomach in both H. pylori-infected
and -eradicated patients, as in IM in Cohort 1 (Supplementary Table S1 ). 
Effects of long-term aspirin use
In H. pylori-infected patients, only miR-34c methylation in AM was significantly lower in the Hp+/LDA/GC group compared to the Hp+/GC group (P=0.047), which may be an effect of long-term aspirin use. In contrast, there were no significant differences in other molecular events between patients taking and patients not taking LDA/NSAIDs in both AM and IM irrespective of H. pylori infection (Table 10 ). 
Discussion
To the best of our knowledge, this is the first study to show the effects of H. pylori eradication and LDA/NSAIDs on the methylation of several miRNAs in patients with and without GC.
Cohort 1
In patients not taking LDA/NDAIDs, H. pylori eradication was able to reverse the 
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Watari J, et al. 14 methylation of most miRNA genes only in AM, but not in IM, in both patients with and without GC (i.e., the Hp+/AG and Hp+/GC groups). In multivariate analysis, H. pylori eradication was associated with a significant reduction of miR-124a-3 methylation in both groups, which was consistent with our previous study [34] . In addition, miR-34c
and miR-129-2 methylation were associated with GC development in H. pylori-infected cases, and only miR-129-2 methylation in AM was an independent risk marker of significant GC.
When evaluating the differences in the methylation of miRNA genes in each of the three parts of the stomach, we found that miR-34c methylation in AM in the antrum and corpus portions and miR-129-2 methylation in AM in the corpus might be useful biomarkers of GC in H. pylori-infected patients. Meanwhile, miR-129-2 methylation in AM in the angulus was associated with GC development in H. pylori-eradicated patients, thus indicating that biomarkers for GC differ for each part of the stomach according to H. pylori status. Suzuki et al. reported that miR-34b/c methylation in the corpus is an independent predictor of metachronous GC risk [37] . However, they did not investigate the methylation of miRNA genes in AM and IM separately in H. pylori-infected and -eradicated patients.
Cohort 2
In patients taking LDA/NSAIDs, the incidence of miRNA gene methylation was not different between H. pylori-infected and -eradicated patients in both AM and IM.
Meanwhile, miR-129-2 methylation in AM was significantly involved in GC development in H. pylori-eradicated patients. Therefore, this result indicates that patients with miR-129-2 methylation in AM, especially in the antrum, may be at risk of GC. In the present study, LDA/NSAIDs decreased miR-34c methylation in AM in H.
pylori-infected patients with GC (Table 10 ). This result may suggest that the chemopreventive effect of aspirin is limited to AM, but not to IM, in H. pylori-infected patients. Some studies showed in stratified analysis that the chemopreventive effect of aspirin was higher in H. pylori-infected subjects [42] [43] [44] ; this finding was in agreement with our results from the viewpoint of miRNA analysis. However, as H. pylori status was judged using only H. pylori IgG antibody in those previous studies [42] [43] [44] , no precise diagnosis of H. pylori infection was performed. In addition, it may be possible that the H. pylori-negative subjects in those studies included two subtypes that were completely different in terms of their GC risk: H. pylori-uninfected patients and patients who were suspected of naturally eradicated H. pylori. In our study, we showed that long-term use of LDA/NSAIDs did not affect the changes in miRNA methylation in either H. pylori-infected or -eradicated patients. However, Cheung et al. recently
reported using molecular pathological analysis that the protective effect of aspirin appeared to be larger in H. pylori-eradicated subjects (Hazard ratio=0.30) [45] , a finding that was different from our results. Therefore, the mechanism of the chemopreventive effect of aspirin cannot be explained by miRNA methylation alone.
In the present study, the methylation of tumor-suppressor miRNAs was identified more frequently in IM and very infrequently in AM. It thus appears that the methylation of these genes is a molecular event that occurs specifically in IM, and also that IM might exhibit a more aggressive state than AM with regard to molecular alterations, as shown in our previous reports [33, 34] . Intriguingly, only in H. pylori-eradicated patients, the number of IM samples obtained from three parts of the stomach was significantly higher in patients with GC (the Hp-/GC and Hp-/LDA/GC groups) than in those without GC (the Hp-/AG and Hp-/LDA/AG groups). This result may support the clinical fact that GC is related to the extent of IM throughout the stomach [46] , especially after H. pylori treatment. Also, H. pylori eradication and long-term use of LDA/NSAIDs reversed the methylation of miRNAs in AM, but not in IM. Taken together, these results are in agreement with the concept of a "point of no return" [47] in which the benefits of H. pylori eradication and aspirin diminish after the IM stage is reached through the state in which molecular changes are irreversible.
The present study had a methodological advantage: as our data from LCM samples delineated many GC-related miRNA genes, this procedure might provide more information from AM and IM regarding pathogenesis than would the use of whole tissue material [48] . Since whole biopsy tissues were used for DNA methylation analysis in the previous studies [29, 30, [36] [37] [38] [39] [40] [41] , the differences in methylation between AM and IM were not evaluated. Therefore, those results may be affected by the amount of IM glands contained in the biopsy samples.
Our investigation had some limitations. First, this was a study from a single institution with a small number of H. pylori-infected patients who were taking LDA/NSAIDs, especially considering that three different gastric portions of molecular alterations were compared. The second limitation is that this study may have been biased by using the same samples collected in our previous two studies [33, 34] . Third, a relatively high number of samples could not be analyzed for molecular alterations due to the small amount of DNA that was extracted from the very small biopsy specimen.
Therefore, further prospective studies with a larger sample size are needed to clarify the association between miRNAs and gastric carcinogenesis in the background mucosa with and without GC.
Materials and Methods
Cohort 1
Patients
We previously conducted a cross-sectional study to define the differences in molecular alterations in AM and IM before and after H. pylori eradication (≥3 yr) in patients with and without GC [28, 33, 34] . By using the same samples, we herein performed a case-control study on miRNAs in four groups of the same patients based on the previous studies [28, 33, 34] : patients with histologically diagnosed AG (GC-free patients) who were positive for H. pylori (Hp+/AG group, n=21); GC patients with H. pylori infection (Hp+/GC group, n=26); patients with histologically diagnosed AG (i.e., GC-free patients) who had undergone H. pylori eradication >3 years before and had AG in the background mucosa (Hp-/AG group, n=30); and patients who developed primary early GC despite the successful eradication of H. pylori at >3 years before (Hp-/GC group, n=27). Histological diagnosis of GC was made in accordance with the GC criteria of the Japanese Gastric Cancer Association [49] . Patients with a history of esophagectomy or gastrectomy and who were taking LDA or other NSAIDs were excluded.
H. pylori status and DNA extraction
In our previous studies [28, 33, 34] , three biopsy specimens were taken from three parts of the stomach, the greater curvature at the antrum and corpus and the lesser curvature at the angulus (one from each site) during an endoscopy. Figure S1) . Finally, a total of 307 biopsy samples from 104 patients including the Hp+/AG, Hp+/GC, Hp-/AG, and
Hp-/GC groups were analyzed. However, five samples could not be analyzed for molecular alterations due to the small amount of DNA that was extracted from the very small biopsy specimens.
Sodium bisulfite modification of DNA of miRNA genes
Similar to previous reports [28, 33, 34] , purified DNA samples were chemically modified by sodium bisulfite with an EpiTect ® Fast Bisulfite Kit (Qiagen). The bisulfite-modified DNA was amplified using primer pairs that specifically amplify the methylated or unmethylated sequences of several miRNAs related to carcinogenesis, including miR-34c, miR-124a-3, miR-129-2, and miR-137.
Methylation-sensitive high-resolution melting (MS-HRM) analyses
polymerase chain reaction (PCR) amplification and MS-HRM analysis were performed using a LightCycler ® 480 System II (Roche, Mannheim, Germany). The primer sequences of all genes for the methylated and unmethylated forms and PCR and MS-HRM conditions are summarized in Supplementary Tables S2 and S3 . Percentages of methylation (0%, 10%, 50%, and 100%) were used to draw the standard curve (Supplementary Figure S2) . In this study, only samples with >10% methylation were considered to be methylated as reported previously [33, 34] .
Cohort 2
Patients and samples
In this study, which was based on our previous studies [28,33], we analyzed 22 patients who had developed primary GC despite taking LDA (100 mg/day) or NSAIDs for more than 3 years. These patients included 11 H. pylori-infected patients (Hp+/LDA/GC group) and 11 H. pylori-eradicated patients (Hp-/LDA/GC group). We also analyzed 24 patients with histologically diagnosed AG (GC-free patients) who regularly took LDA or NSAIDs for more than 3 years, who included H. pylori-infected cases (n=3, Hp+/LDA/AG group) and H. pylori-eradicated cases (n=21, Hp-/LDA/AG group).
Biopsy specimens were taken from the same portions in the same manner as described in Cohort 1. Patients with a history of esophagectomy or gastrectomy were excluded.
In Cohort 2, the methylation of miRNAs was analyzed. A total of 137 biopsy samples from 46 patients including the Hp+/LDA/AG, Hp+/LDA/GC, Hp-/LDA/AG, and Hp-/LDA/GC groups were analyzed. However, one sample could not be analyzed for molecular alterations due to the small amount of DNA that was extracted.
Consent and institutional review board approval
Written informed consent was obtained from all patients prior to this study. The Ethics
Committee of Hyogo College of Medicine approved these studies (Nos. Rin-Hi 136 and 300). These trials were registered with the UMIN Clinical Trials Registry (No. UMIN000021857). The study was performed in accordance with the Declaration of Helsinki.
Statistical analysis
Categorical variables were presented by number and percentage and compared using the and StatView version 5.0 (SAS Institute Inc., Cary, NC).
Conclusions
In patients who were not taking LDA/NSAIDs (Cohort 1), (1) H. pylori eradication was associated with a significant reduction of miR-124a-3 methylation only in AM in the background mucosa with and without GC, but not in IM, and (2) 
